{"@id":"https://bioecon.ru/technology/conditionally-active-nanobody-drug-conjugates/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://en.bioecon.ru/technology/conditionally-active-nanobody-drug-conjugates/","json":"https://en.bioecon.ru/api/v1/technology/conditionally-active-nanobody-drug-conjugates/index.json"},"id":"conditionally-active-nanobody-drug-conjugates","industries":["pharma","biomanufacturing"],"lang":"en","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/jiangsu-hengrui-medicine/","https://bioecon.ru/companies/daiichi-sankyo/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/insilico-medicine/","https://bioecon.ru/companies/isomorphic-labs/","https://bioecon.ru/companies/atomwise/","https://bioecon.ru/companies/ecowin/","https://bioecon.ru/companies/fermelanta/","https://bioecon.ru/companies/esco-aster/"]},"maturity":7,"name":"Conditionally Active Nanobody-Drug Conjugates","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"pH/ATP-sensitive library panning"},{"n":2,"title":"Site-specific payload conjugation"},{"n":3,"title":"Tumor penetration validation"},{"n":4,"title":"Systemic safety and clearance"}],"summary":"Single-domain VHH antibodies engineered to bind antigens exclusively in acidic or hypoxic tumor microenvironments, delivering cytotoxic payloads without on-target off-tumor systemic toxicity.","url":"/technology/conditionally-active-nanobody-drug-conjugates/","verified":"2026-11-22"}